Drug Type Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism PDL2 inhibitors(Programmed cell death 1 ligand 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma, Cutaneous Malignant | Phase 1 | United States | 08 Apr 2008 | |
Metastatic melanoma | Phase 1 | United States | 08 Apr 2008 |